Real-time clinical trials are now live.
A pure transcript-based reading of the FDA event, organized as a multi-page card experience. Each card opens a dedicated page with supporting ideas from the transcript.
Main takeaways from the transcript
Select a card to open its supporting detail page.
The current process has too much dead time
The transcript says 45% of the time between Phase 1 and the final FDA application is dead time, with no ongoing clinical trial.
FDA says the first real-time clinical trial is already live
The transcript describes a live real-time trial, not a future framework, where reviewers can see agreed-upon signals in the cloud as the trial happens.
FDA and sponsors said this does not mean less rigor
Multiple speakers stressed that this new approach is not about weakening science or reducing safety standards.
Technology is the enabler, not the whole story
The transcript points to cloud computing, electronic health records, and AI tools, but always inside a broader process redesign story.
Speakers tied the effort to patient access and broader participation
The transcript says integrated data-driven approaches can bring research closer to patients and help reduce barriers to participation.
The real-time trial was presented as part of a bigger FDA re-engineering effort
The transcript places the real-time trial inside a larger push to re-engineer more of the drug development and approval process.
Clean transcript-based summary
FDA said the current drug development process has accepted too much delay for too long. Commissioner Marty Makary said about 45% of the time between a Phase 1 trial and the final FDA application is “dead time,” meaning there is no ongoing clinical trial while investigators and staff are tied up with paperwork and other tedious tasks.
He also said applications can become absurdly large, citing one case of 66 million pages. His message was simple: the system can do better.
The headline announcement was that the first real-time clinical trial is already live. FDA described this as a trial where reviewers can see agreed-upon safety signals and clinical endpoints in the cloud as the trial is happening. The examples given were a fever, a hospitalization, or a tumor shrinking and being read by a radiologist.
Makary said this is not just a theoretical plan or future framework. He described it as up and running now and called it a milestone toward a broader goal of more continuous trials and less lag between phases.
Other speakers reinforced the same basic message. The opportunity is to move useful data faster across the clinical research ecosystem, to bring research closer to patients, and to reduce barriers to participation. But they were equally clear that this does not mean less rigor. Protocol development, protocol oversight, informed consent, monitoring, governance, FDA review, patient safety, and data integrity all remain essential.